V441

**V441** is a Merck-developed investigational pediatric hexavalent combination vaccine evaluated in healthy infants. It combines antigens intended to induce active immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive *Haemophilus influenzae* type b disease. A completed registration study in Taiwan, V441-001, assessed its safety, tolerability, and immunogenicity. Publicly available trial information identifies V441 as a DTaP-IPV-HepB-Hib combination vaccine but does not establish a marketed brand name or confirm that it is identical to a later marketed hexavalent vaccine.

Other names

diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B recombinant, and Haemophilus influenzae type b conjugate vaccine